PMID- 28763435
OWN - NLM
STAT- MEDLINE
DCOM- 20180423
LR  - 20210504
IS  - 1643-3750 (Electronic)
IS  - 1234-1010 (Print)
IS  - 1234-1010 (Linking)
VI  - 23
DP  - 2017 Aug 1
TI  - Therapeutic Effect of Sodium Glucose Co-Transporter 2 Inhibitor Dapagliflozin on 
      Renal Cell Carcinoma.
PG  - 3737-3745
AB  - BACKGROUND Patients with type 2 diabetes mellitus (T2DM) have a high incidence of 
      renal cell carcinoma (RCC) and high sodium glucose co-transporters 2 (SGLT2) 
      expressions. The purpose of this study was to evaluate the anticancer activity of 
      dapagliflozin as an SGLT2 inhibitor on RCC cell lines in vitro and in vivo. 
      MATERIAL AND METHODS qRT-PCR and Western blot were used to detect SGLT2 
      expression on different human renal cells. Then, flow cytometry and 
      immunofluorescence were used to investigate the effects of dapagliflozin on cell 
      cycle, apoptosis, and SGLT2 expression of CaKi-1 cells. Finally, a xenograft 
      model and immunohistochemical staining were used to investigate the function of 
      dapagliflozin in nude mice. RESULTS We proved that SGLT2 is highly expressed in 
      RCC cell lines. We found that dapagliflozin exerts a higher cytotoxic effect on 
      human RCC than on normal human renal cells, regulates the cell cycle and 
      apoptosis, and reduces the glucose uptake and SGLT2 expression of CaKi-1 cells. 
      Moreover, dapagliflozin inhibits tumor growth and reduces SGLT2 expression in 
      vivo. CONCLUSIONS Our results indicate that dapagliflozin has high efficiency and 
      low toxicity and could be a new therapeutic target for RCC.
FAU - Kuang, Haoyu
AU  - Kuang H
AD  - Department of Laboratory, The Fifth Affiliated Hospital, Sun Yat-sen University, 
      Zhuhai, Guangdong, China (mainland).
FAU - Liao, Liya
AU  - Liao L
AD  - Department of Laboratory, The Fifth Affiliated Hospital, Sun Yat-sen University, 
      Zhuhai, Guangdong, China (mainland).
FAU - Chen, Hongtao
AU  - Chen H
AD  - Department of Laboratory, The Fifth Affiliated Hospital, Sun Yat-sen University, 
      Zhuhai, Guangdong, China (mainland).
FAU - Kang, Qian
AU  - Kang Q
AD  - Department of Laboratory, The Fifth Affiliated Hospital, Sun Yat-sen University, 
      Zhuhai, Guangdong, China (mainland).
FAU - Shu, Xiaochun
AU  - Shu X
AD  - Department of Laboratory, The Fifth Affiliated Hospital, Sun Yat-sen University, 
      Zhuhai, Guangdong, China (mainland).
FAU - Wang, Yanan
AU  - Wang Y
AD  - Department of Laboratory, The Fifth Affiliated Hospital, Sun Yat-sen University, 
      Zhuhai, Guangdong, China (mainland).
LA  - eng
PT  - Journal Article
DEP - 20170801
PL  - United States
TA  - Med Sci Monit
JT  - Medical science monitor : international medical journal of experimental and 
      clinical research
JID - 9609063
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Glucosides)
RN  - 0 (RNA, Messenger)
RN  - 0 (Sodium-Glucose Transporter 2)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 1ULL0QJ8UC (dapagliflozin)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Animals
MH  - Apoptosis/drug effects
MH  - Benzhydryl Compounds/pharmacology/*therapeutic use
MH  - Carcinoma, Renal Cell/*drug therapy/pathology
MH  - Cell Cycle/drug effects
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - Glucose/metabolism
MH  - Glucosides/pharmacology/*therapeutic use
MH  - Humans
MH  - Kidney/drug effects/metabolism/pathology
MH  - Kidney Neoplasms/*drug therapy/pathology
MH  - Mice, Nude
MH  - RNA, Messenger/genetics/metabolism
MH  - Sodium-Glucose Transporter 2/genetics/metabolism
MH  - *Sodium-Glucose Transporter 2 Inhibitors
PMC - PMC5549715
COIS- Conflict of interests The authors have declared that no competing interests 
      exist.
EDAT- 2017/08/02 06:00
MHDA- 2018/04/24 06:00
PMCR- 2017/08/01
CRDT- 2017/08/02 06:00
PHST- 2017/08/02 06:00 [entrez]
PHST- 2017/08/02 06:00 [pubmed]
PHST- 2018/04/24 06:00 [medline]
PHST- 2017/08/01 00:00 [pmc-release]
AID - 902530 [pii]
AID - 10.12659/msm.902530 [doi]
PST - epublish
SO  - Med Sci Monit. 2017 Aug 1;23:3737-3745. doi: 10.12659/msm.902530.